8-K: Mirum Pharmaceuticals Reports Strong Q1 2025 Results, Raises Full-Year Revenue Guidance

Mirum Pharmaceuticals announces positive Q1 2025 financial results, highlighted by $111.6 million in revenue and increased full-year revenue guidance to $435-$450 million.

Summary

• Mirum Pharmaceuticals reported first quarter 2025 financial results and provided a business update.
• Total revenue for Q1 2025 was $111.6 million, compared to $69.2 million for Q1 2024.
• The company increased its full-year revenue guidance to $435 to $450 million.
• LIVMARLI net product sales were $73.2 million in Q1 2025, a 71% increase year-over-year.
• Bile Acid Medicines net product sales were $38.4 million, a 47% increase year-over-year.
• The FDA approved LIVMARLI oral tablet formulation.
• LIVMARLI was also approved in Japan for ALGS and PFIC.
• CTEXLI (chenodiol) was approved in the US for cerebrotendinous xanthomatosis.
• The VISTAS study of volixibat in PSC is expected to complete enrollment in the third quarter of 2025, with topline data expected in the second quarter of 2026.
• The VANTAGE study of volixibat in PBC is expected to complete enrollment in 2026.
• The LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is expected to complete enrollment in 2026.
• Mirum expects to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
• As of March 31, 2025, Mirum had $298.6 million in unrestricted cash, cash equivalents, and investments.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, increased revenue guidance, and regulatory approvals. While operating expenses have increased, the overall tone is optimistic due to commercial growth and pipeline advancements.

Positives

• Strong revenue growth in Q1 2025, with total revenue increasing to $111.6 million.
• Increased full-year revenue guidance indicates confidence in continued growth.
• Significant growth in LIVMARLI sales, demonstrating strong market adoption.
• Approval of LIVMARLI oral tablet formulation provides a more convenient option for patients.
• Regulatory approvals in Japan and the US expand the market reach for LIVMARLI and CTEXLI, respectively.
• The company maintains a strong cash position with $298.6 million in cash, cash equivalents, and investments.

Negatives

• Total operating expenses increased to $126.8 million for the quarter ended March 31, 2025, compared to $95.7 million for the quarter ended March 31, 2024.
• The company reported a net loss of $14.677 million, or $0.30 per share, for the quarter ended March 31, 2025.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's business is subject to general risks and uncertainties, including the impact of geopolitical and macroeconomic events.
• Worsening of liver function is a potential risk associated with CHOLBAM treatment.
• Liver injury is a potential side effect of LIVMARLI and CTEXLI.

Future Outlook

Mirum Pharmaceuticals increased its full-year revenue guidance to $435 to $450 million and anticipates continued progress across its commercial medicines and pipeline.

Management Comments

• Its been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline, said Chris Peetz, chief executive officer of Mirum.
• Were pleased with the FDAs approval of LIMARLIs tablet formulation, which provides more options for the ALGS and PFIC community in the U.S. in the form of a convenient single tablet dose.
• Our VISTAS study of volixibat in PSC is enrolling well and we expect to complete enrollment in the third quarter of this year.
• Were excited to continue our strong execution across our commercial medicines and pipeline throughout the year.

Industry Context

Mirum's focus on rare liver diseases positions it within a niche market with limited competition, allowing for strong growth potential with successful drug development and commercialization. The approval of LIVMARLI in new formulations and territories, along with the advancement of volixibat, strengthens its competitive position.

Comparison to Industry Standards

• Mirum's revenue growth in Q1 2025 significantly outpaces the average growth rate for pharmaceutical companies in the rare disease space.
• Companies like Biomarin Pharmaceutical and Vertex Pharmaceuticals, which also focus on rare diseases, have similar revenue profiles but operate in different therapeutic areas.
• The successful commercialization of LIVMARLI and the potential approval of volixibat could position Mirum as a leader in the treatment of cholestatic liver diseases, comparable to companies like Intercept Pharmaceuticals in the NASH space.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased revenue guidance.
• Patients with rare liver diseases will benefit from the availability of new treatment options and formulations.
• Employees may experience increased job security and growth opportunities due to the company's success.
• The company's financial stability strengthens its relationships with suppliers and creditors.

Next Steps

• Complete enrollment in the VISTAS study in Q3 2025.
• Present interim data from the VANTAGE study at EASL on May 9th.
• Complete enrollment in the VANTAGE study in 2026.
• Complete enrollment in the LIVMARLI EXPAND Phase 3 study in 2026.
• Initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome in 2025.

Key Dates

Keywords

Mirum Pharmaceuticals, LIVMARLI, Volixibat, CHOLBAM, CTEXLI, Financial Results, Revenue Guidance, Rare Diseases, IBAT Inhibitor, ALGS, PFIC, PSC, PBC, Fragile X Syndrome, MRM-3379